Novo Nordisk A/S (NOVO-B.CO) reported Q3 2026 results on 4 Nov 2026. Earnings per share came in at DKK 5.79, against an analyst average of DKK 4.92, a surprise of +17.8%.
Revenue: DKK 79.2B vs DKK 73.8B expected. The quarter ended on 30 Sep 2026.
The company is valued at about DKK 1.3T.
Figures from Yahoo Finance at the time of writing. Not investment advice.